NGP 555 is primarily investigated for its potential therapeutic applications in neurodegenerative diseases, particularly Alzheimer's disease. It is being studied as a small molecule inhibitor that targets amyloid-beta production, a key factor in the progression of Alzheimer's. By modulating gamma-secretase activity, NGP 555 aims to reduce the formation of toxic amyloid-beta peptides, which are implicated in the development of amyloid plaques in the brain. This approach holds promise for slowing or halting disease progression. Research is ongoing to evaluate its efficacy, safety, and potential as a disease-modifying treatment in clinical trials.